Expectations, positive or negative, are modulating factors influencing behavior. They are also thought to underlie placebo effects, impacting perceptions and biological processes. Using healthy human subjects, we examined the role of the nucleus accumbens (NAC), a region centrally involved in the encoding of reward expectation, in the formation of placebo responses. Employing functional molecular imaging, activation of NAC dopamine (DA) release was observed during placebo administration and related to its anticipated effects, perception-anticipation mismatches, and placebo effect development. In additional functional MRI studies, the expectation of monetary gain increased NAC synaptic activity in a manner proportional to placebo-induced DA release, anticipated effects, perception-anticipation differentials, and actual placebo effects. Individual variations in NAC response to reward expectation accounted for 28% of the variance in the formation of placebo analgesia.
INTRODUCTION
A common phenomenon across a variety of human experiences is the extent to which our expectations about an event, whether positive or negative, direct behavior to ensure future reward acquisition or to avoid potential harm. It is thought that these effects are mediated by specific neuronal circuits linking cognitive, emotional, and motor responses traditionally studied in the context of the pursuit of natural (e.g., food), monetary, and drug rewards (Kalivas et al., 1999; Mogenson and Yang, 1991; Tom et al., 2007) . However, individual expectancies also shape the actual perception and experience of events, not just motivated behavior. For example, the anticipation that a noxious challenge would be of higher or lower intensity has been shown to increase and diminish subjective report, as well as the brain regional responses to otherwise identical stimuli. The neural effects have consistently involved the anterior cingulate and posterior insula, areas implicated in the perception and regulation of pain signals (Keltner et al., 2006; Koyama et al., 2005; Sawamoto et al., 2000) . Environmental challenges threatening homeostasis and positive expectations capable of reducing the bodily response are therefore interacting with each other conferring vulnerability and resiliency, respectively. These effects are thought to be the basis for the formation of placebo effects and point to individual expectancies as important modifiers of biological processes in both health and disease. However, the processes by which anticipation translates into measurable biological responses are unknown, this being a question of profound relevance to medicine and human biology. Placebo effects are an important confound in medical trials (Hrobjartsson and Gotzsche, 2001 ), while at the same time they represent a resiliency mechanism favoring homeostasis. The larger the anticipated benefit from a drug or a procedure, typically the greater is the actual health improvement observed (de Craen et al., 2000; Moseley et al., 2002) .
In nonhuman primates and rodents, brainstem ventral tegmental area (VTA) dopaminergic cells projecting to the nucleus accumbens (NAC) of the ventral basal ganglia respond to both the magnitude of anticipated rewards and deviations from the predicted outcomes, serving as an adaptive system modulating behavioral responses (Schultz, 2006; Setlow et al., 2003; Tobler et al., 2005) . Based on this information and if the placebo effect is considered a form of reward anticipation response, it has been hypothesized that the activity of mesolimbic dopamine (DA) cells during reward anticipation and their capacity to adapt to environmental information underlies placebo responding in humans (Fields, 2004; Irizarry and Licinio, 2005) . DA activation in the NAC has been detected with positron emission tomography (PET) during receipt of a placebo in patients diagnosed with Parkinson's disease in a manner proportional to the anticipated improvement in motor control (de la Fuente-Fernandez et al., 2002) . However, no relationship was found between NAC DA activity and the actual placebo effects on motor function. These were, in fact, ascribed to DA activity in nigrostriatal projection regions (caudate and putamen) (de la FuenteFernandez et al., 2001) . Along similar lines, Petrovic and collaborators, using functional magnetic resonance imaging (fMRI) (Petrovic et al., 2005) , described a correlation between ratings of negative affect improvement during preconditioning with a benzodiazepine and ventral basal ganglia synaptic activity after receipt of a placebo. These reports seem to confirm an involvement of NAC DA and synaptic activity in the expectations created by the introduction of a placebo, or in the case of the latter work, in conditioned responses. Nevertheless, how these effects are related to actual placebo effects and whether individual differences in NAC function underlie individual variations in the biological effects of placebos remains unknown. Alternatively, placebo-associated changes in NAC and mesolimbic DA function could simply form part of an epiphenomenon related to the organism response to a salient stimulus (i.e., the placebo) without physiological relevance other than directing attention to that stimulus.
These questions were examined in a sample of healthy humans with a combination of studies employing PET and [ 11 C]raclopride and fMRI. The studies were described as a randomized control trial of a novel analgesic agent and that either a placebo or an active agent could be administered. In that manner, we hoped to elicit a full range of expectations and placebo effects that would allow the study of interindividual differences in these phenomena. The placebo consisted of 1 ml of isotonic saline delivered intravenously every 4 min. The 20 min pain expectation periods were followed by an actual pain challenge that was maintained for 20 min. Molecular imaging was employed to measure placebo-induced DA release during the pain expectation state. This would be reflected by reductions in the in vivo receptor availability (binding potential, BP) during pain anticipation scans when the placebo was administered. To determine whether individual differences in placebo effects are related to variations in the biological response to reward anticipation, subjects also underwent an fMRI study using the Monetary Incentive Delay (MID) task. This task activates NAC synaptic activity during the anticipation of a reward (Knutson et al., 2004) . Interindividual variations in NAC DA responses to placebo administration were then compared with the synaptic activity of the same region during anticipation of a monetary reward. Both these measures were then examined as a function of the anticipated analgesic effects of the placebo, deviations from those expectations, and the magnitude of placebo analgesic effects in pain challenges. It was hypothesized that in healthy subjects, in the absence of underlying pathology or previous conditioning, interindividual variations in placebo-induced NAC DA activity and in the synaptic activity of this region during reward anticipation would be related to the variability in placebo effects obtained in the studies.
RESULTS

Dopaminergic Mechanisms in the Formation of Placebo Effects
Fourteen of the volunteers (seven male, seven female) participated in the functional molecular PET and [ 11 C]raclopride studies. This is a DA D2 receptor radioligand that also labels D3 receptors in the NAC (Seeman et al., 2006) . Each subject was studied during conditions of expectation of a painful challenge with and without the administration of a placebo with potential analgesic properties. Anticipated analgesia ratings averaged 37 ± 26 (mean ± 1 SD) (range 0-95), using a 0-100 visual analog scale (VAS = 0 not expected to be effective, 100 complete effectiveness). These studies were followed by actual pain challenges, with and without placebo administration, lasting for 20 min each ( Figure 1A ). Subjective ratings of placebo analgesia acquired at that time were rated at 35 ± 30 (range 0-80, with 0 = completely ineffective and 100 = completely effective). The mismatch between anticipated and perceived placebo effects was also computed (analgesia perceived minus anticipated, 2 ± 31, range 60 to À60).
Prior to the induction of pain, placebo effects during pain expectation were determined using the Positive and Negative Affectivity Scale (PANAS; Watson et al., 1988) affect ratings. Placebo administration was associated with reductions in PANAS negative affect ratings (2.3 ± 2.4 without placebo to 1.5 ± 2.7 with placebo, one-tail paired t test, t = 2.8, p < 0.01). Fear ratings were also reduced (2.2 ± 2.2 to 1.0 ± 2.0, t = 4.5, p = 0.001), while positive affect ratings showed a trend toward increases (6.9 ± 6.1 without placebo to 9.5 ± 9.2 with placebo, t = 1.6, p < 0.08).
In the pain challenges that followed, placebo-induced analgesic effects were determined by contrasting studies with and without the administration of the placebo using the change in pain intensity ratings acquired every 15 s for the 20 min duration of the challenges (df = 13, paired one-tail t tests). For the entire sample, the average pain intensity ratings were 33 ± 14 without and 27 ± 12 with placebo (average within subject reduction 6 ± 10 VAS units, t = 1.8, p = 0.04) ( Figure 1C ).
We also examined whether placebo effects on pain ratings could be explained by the order in which the studies were conducted, as placebo administrations always followed pain challenges to provide a frame of reference to the subjects. For this purpose, a separate sample of 18 healthy males 20-30 years of age was studied twice with the same experimental protocol, except that no scanning was performed and subjects did not receive the placebo. Average VAS pain intensity ratings over 20 min were 32 ± 13 for studies conducted first in order, and 31 ± 13 for those second in order (paired one-tail t test, t = 0.6, p = 0.3).
Significant differences for the change in pain ratings between placebo and no intervention group were obtained, confirming the development of a placebo analgesia that was not confounded by order effects (two-sample, one-tail t test, t = 2.1, p = 0.02). Pain ratings over time during the no intervention studies are shown in Figure 1D .
Analgesic effects were also examined as a function of time (divided into acute, tonic, and sustained pain phases) to determine whether one or more parts of the 20 min pain challenge were more susceptible to placebo analgesic effects and for comparability with pain models of shorter duration (Grevert and Goldstein, 1977; Amanzio and Benedetti, 1999) . For the initial acute pain intensity ratings (peak rating after a 0.15 ml bolus of 5% hypertonic saline administered over 15 s) pain ratings were 60 ± 23 VAS intensity units before and 56 ± 18 after placebo (t = 0.9, p = 0.2). Ratings over the first 10 min of the challenge (tonic pain) were 33 ± 16 (pain) and 27 ± 10 (pain + placebo) (t = 1.6, p = 0.06). During the last 10 min of the challenge (sustained pain phase), these were 33 ± 15 (pain) and 26 ± 14 (pain + placebo) (t = 2.4, p = 0.02). Placebo effects then appeared more prominent for tonic or more sustained phases of pain, as opposed to brief, phasic pain ( Figure 1C ).
The anticipation of analgesia was significantly and positively correlated with the average reduction in pain ratings during pain + placebo studies (r = 0.48, p < 0.05), as was the difference between perceived and anticipated analgesia (r = 0.54, p < 0.05).
For analyses of imaging data, individuals were grouped into high and low placebo analgesia responders using the median value of the average change in pain intensity ratings over the 20 min challenges. Placebo responders above the median (high responders) showed average reductions in pain intensity of 11 ± 7 VAS units ( Figure 1C) , while a À0.2 ± 10 VAS intensity unit reduction was recorded in placebo responders below the median (low placebo responders) (n = 7 in each group).
In the DA receptor quantification scans acquired during pain expectation, volumes of interest placed in the NAC bilaterally demonstrated placebo-induced activation of DA D2/D3 neurotransmission, evidenced by significant reductions in BP. These averaged 11.0% in the left and 8.1% in the right NAC (left NAC BP, 1.3 ± 0.2 without and 1.2 ± 0.3 with placebo, paired one-tail t test, t = 2.5, p < 0.02; right NAC BP, 1.7 ± 0.3 without and 1.6 ± 0.4 with placebo, paired one-tail t test, t = 1.8, p = 0.05) ( Figure 1B) . No significant sex differences in placeboinduced DA release were obtained, nor correlations between DA release and estradiol or progesterone plasma levels in females (p > 0.05). Progesterone levels were uniformly low for this sample of women, who were studied in the follicular phase of the menstrual cycle.
No significant correlations were obtained between the placebo effect during pain expectation trials (the change in PANAS negative, positive, or fear scores with placebo) and right or left NAC DA activity (p > 0.05). However, when subjects were grouped into high and low placebo responders using a median split of the placebo-induced change in positive affect during pain expectation, significant differences in DA activation were obtained in the left NAC (high responders 20 ± 16%, low responders 2 ± 11% change in BP, t = 2.3, p = 0.02). Effects in the same direction were obtained for the right NAC, but did not reach statistical significance (high responders 9 ± 14%, low responders 2 ± 6% change in BP, t = 1.2, p = 0.1). No significant differences in placebo-induced NAC DA release were obtained for subject groupings using placeboinduced changes in PANAS negative affect or fear ratings (p > 0.05).
The magnitude of placebo-induced DA activation in the NAC, bilaterally, was positively associated with the anticipated effectiveness of the placebo as rated by the volunteers prior to its introduction (right, r = 0.69, p < 0.005; left, r = 0.67, p = 0.005) ( Figure 2A ). More relevant to the elicitation of placebo analgesic effects, similar relationships were obtained between placebo-induced NAC DA activation and the mismatch between its perceived effectiveness and the anticipated placebo analgesia (right, r = 0.46, p < 0.05; left, r = 0.66, p < 0.005) ( Figure 2B ).
The high placebo analgesia group in the pain trials also demonstrated significantly greater magnitudes of right NAC DA responses to placebo during the pain expectation PET studies than low placebo analgesia responders (high placebo analgesia group, 15 ± 13% reduction in DA D2/ D3 BP, low placebo analgesia, 0.4 ± 7%, unpaired onetail t test, t = 2.5, p < 0.02). However, no significant correlations were obtained between these two variables (p > 0.05). No significant effects were obtained for the left NAC in t tests or correlations (p > 0.05).
In the low placebo response group, four individuals reported increases in pain intensity during placebo administration (hyperalgesia during placebo administration, a possible nocebo effect) that reached statistical significance (placebo hyperalgesia group 10.0 ± 2.3 increase in average VAS intensity ratings, remainder of the sample 11.3 ± 10.9 reduction, unpaired t test, t = 5.7, p < 0.0001). These subjects showed lower levels of placebo-induced DA release compared to the remainder of the group in the right NAC, with a mean in the direction of ''deactivation'' (change in BP, hyperalgesia/nocebo responders, 0.2 ± 6.3% increases in BP, remainder of the sample 5.9 ± 10.3% reductions in BP), albeit these differences did not reach statistical significance with the small sample size of the nocebo group. Changes in left NAC DA D2/D3 receptor BP were similar for hyperalgesia/nocebo responders and other subjects, however (hyperalgesia/ nocebo group 6.8 ± 11.7%; others 8.0 ± 8.8%; decreases in BP in both cases).
The results of the functional molecular imaging studies indicate that ventral basal ganglia DA neurotransmission is activated in response to the introduction of a placebo in a manner proportional to its anticipated benefit. The imaging data were obtained in the absence of actual pain (pain expectation periods), and therefore do not represent a response motivated by varying experiences of pain at the time, known to influence placebo responding . They may then more closely relate to individual variations in NAC DA reactivity to salient cues, in this case the placebo, of potential benefit to the subject. In this regard, we show that the difference between subjectively experienced and anticipated placebo effects was related to the magnitude of NAC DA D2/D3 system activation during placebo administration. Furthermore, high placebo analgesia responders in pain trials following the imaging experiments were characterized by more pronounced NAC DA activity during placebo administration in the pain expectation periods that preceded them.
Individual Differences in the Formation of Placebo Effects Reflect Variations in Nucleus Accumbens
Reward Processing Thirty volunteers (23 male, 7 female) were available for additional fMRI studies that involved using the MID task (Knutson et al., 2001) . In this task, subjects were presented with a visual stimulus representing null ($0.00), low ($0.20), intermediate ($1.00), or high ($5.00) monetary reward values. This was followed by an anticipatory state, a neutral target, and the announcement that the expected reward was received (Knutson et al., 2001) . The protocol and responses of the NAC to varying levels of anticipated rewards are shown in Figure 3A .
Significant increases in blood-oxygenation level dependent (BOLD) fMRI signal, reflecting brain neuronal (Knutson et al., 2001 ) was employed to activate brain regions involved in reward processing. A cue representing a monetary value is followed by an anticipation phase and a neutral target requiring button press and presented for variable intervals depending on the previously recorded reaction time of the subject to ensure at least 66% correct target presses. synaptic activity (Logothetis et al., 2001) , were detected in the NAC, bilaterally, during the anticipation of monetary rewards in a manner proportional to reward value, as previously reported (Knutson et al., 2001 ) ( Figure 3B depicts the average changes in right and left NAC BOLD signal). We then tested whether variations in NAC synaptic activity levels during the anticipation of the larger monetary gain ($5.00), compared to the null condition ($0.00), were related to the formation of placebo effects.
In this sample, significant effects of placebo during pain anticipation were obtained for PANAS negative (t = 1.9, p < 0.04) and fear (t = 2.4, p = 0.02), but not positive affect ratings (t = 0.9, p = 0.2). Placebo analgesic effects during pain trials were also significant across the entire group (t = 1.7, p < 0.05).
A significant positive correlation was obtained between right NAC BOLD fMRI activation during monetary reward anticipation and the anticipated effectiveness of the placebo (r = 0.79, p < 0.001), similarly to the results obtained with placebo-induced NAC DA release. Also as observed for placebo-induced NAC DA release, the mismatch between perceived effectiveness and anticipated placebo analgesic effects was positively correlated with NAC synaptic activity during monetary reward anticipation (r = 0.56, p < 0.001).
The relationships between anticipated and subjectively perceived effects of placebo administration and the NAC BOLD response to reward were further explored by grouping subjects into those finding the placebo as more (n = 7), equally (n = 16) or less effective (n = 7) than anticipated. Right NAC responses to small ($0.20), medium ($1.00), and large ($5.00) rewards were examined for these three groups of subjects with two-way ANOVA (independent variables, group and reward level; dependent variable, right NAC BOLD responses). Group 3 reward level interactions were obtained (F = 2.95, p = 0.02). Subjects that found the placebo either more or equally effective than anticipated demonstrated parametrically increasing right NAC responses to increasing levels of expected reward value. Individuals that rated the placebo as less effective than anticipated did not demonstrate parametrically increasing NAC responses as a function of reward values ( Figure 3D ).
Positive correlations were also obtained between fMRI BOLD activation during reward anticipation and the analgesic effects of the placebo during pain trials (the difference between average pain intensity ratings over the 20 min) (r = 0.53, p = 0.02), accounting for 28% of the variance in the formation of placebo analgesia. Furthermore, the magnitude of right NAC synaptic activity during the reward anticipation task was positively correlated with placebo-induced DA activation in the right and left NAC in the 14 volunteers who participated in both PET and fMRI studies (right, r = 0.51, p < 0.04; left, r = 0.52, p < 0.04) (Figure 3C) . No significant sex differences or correlations with estradiol or progesterone were obtained for right NAC BOLD activation (p > 0.05).
In view of previous data linking changes in positive affect and NAC responses to monetary reward (Knutson et al., 2005) , subjects were grouped into high and low placebo responders using the median value of the change in PANAS positive affect score (during pain expectation). Similar median splits were performed for pain intensity ratings in pain trials before and after placebo administration. High PANAS positive placebo responders during pain expectation trials demonstrated significantly greater right NAC activation during monetary reward anticipation than low placebo responders (percent BOLD signal change from null to $5.00 conditions, high PANAS positive affect responders, 0.82 ± 0.45%, low PANAS responders 0.56 ± 0.38%, unpaired one-tail t test, df = 28, t = 1.7, p < 0.05). However, no significant correlations were obtained between the placebo-induced change in PANAS positive or negative affect during pain expectation and NAC activity during anticipation of reward (p > 0.05).
When subjects were grouped as high or low placebo responders using the analgesic effect of the placebo during pain trials as the classifying factor, high placebo analgesia responders also demonstrated greater right NAC responses during reward anticipation (percent BOLD signal change from null to $5.00 conditions, high placebo analgesia group 0.76 ± 0.45%, low analgesia group 0.48 ± 0.31%, unpaired one-tail t test, df = 28, t = 1.9, p < 0.05).
In the sample studied with fMRI, 8 subjects demonstrated hyperalgesia during placebo administration (possible nocebo response): 11.4 ± 7.9 increase in average intensity pain ratings; reminder of the sample, 12.5 ± 6.7 reduction in pain ratings. Right NAC BOLD signal during monetary reward anticipation was significantly lower in the hyperalgesia/nocebo group compared to the rest of the subjects (hyperalgesia/nocebo group 0.4 ± 0.3% increase in NAC BOLD signal; others, 0.8 ± 0.6% increase in BOLD, unpaired one-tail t test, t = 2.0, p < 0.03).
DISCUSSION
The present report implicates NAC DA in placebo responses when there is anticipation of analgesia. We utilized an experimental design similar to those of clinical randomized controlled trials (no preconditioning or subject preselection, no deception, either an active or an inactive drug could be administered), allowing for a full range of expectations and placebo effects. This design was associated with relatively modest placebo effects across the entire sample, but permits the assessment of individual variations in this phenomenon. The introduction of a placebo was associated with the activation of DA neurotransmission and D2/D3 receptors in a manner proportional to the anticipated analgesic effects of the otherwise inert agent, as well as with the difference between anticipated and subjectively perceived effectiveness of the placebo. The magnitude of placebo-induced DA responses, measured during expectation of pain, further predicted the subsequent development of placebo-induced analgesia in pain trials.
These findings point to individual variations in response to positive expectations, in this case elicited by the administration of a placebo and the relationship between anticipated and perceived outcomes as cognitive elements associated with placebo-induced activation of NAC DA neurotransmission.
In additional studies, we examined whether individual variations in the synaptic activity of the NAC during a task involving the anticipation of a monetary reward would be predictive of the level of placebo effects. Recent data in animal models has shown that DA cells innervating the NAC encode expected reward values, but also deviations from the expected outcomes (Tobler et al., 2005) . While it has been postulated that these mechanisms may underlie placebo effects, the data so far acquired by various groups has not demonstrated that NAC function, whether measured as DA release or as synaptic activity with fMRI, is related to the formation of observable placebo effects. In an initial report, NAC DA release as measured with PET and [
11 C]raclopride during placebo administration in patients diagnosed with Parkinson's disease was related to the expected improvement in motor control but not to the observed changes in motor function (de la Fuente-Fernandez et al., 2001 . Subsequent work using fMRI and a negative emotional challenge showed that the subjective report of treatment efficacy during preconditioning with a benzodiazepine anxiolytic was correlated with NAC synaptic activity during administration of a placebo, but no relationship between NAC activity and placebo effects was found (Petrovic et al., 2005) .
Here, subjects underwent an fMRI protocol involving anticipation of a monetary reward. It was shown that individuals that activated NAC synaptic function to a greater extent during monetary reward anticipation also showed more profound placebo responses. These included greater positive affect scores during pain expectation periods and greater levels of analgesia in pain trials. The NAC BOLD response during monetary reward anticipation was further correlated with placebo-induced DA activity, showing that individual differences in the placebo response could be attributed to differences in NAC function at the levels of DA neurotransmission and synaptic activity during reward expectation. In fact, NAC synaptic activation during anticipation of the (high) monetary reward accounted for approximately one third of the variance in the development of placebo-induced analgesia. In a manner similar to the results obtained with NAC DA responses to placebo, the activation of NAC synaptic activity during reward expectation was significantly correlated to the difference between the anticipated and subjectively perceived analgesic effects of the placebo. It should be noted that the fMRI studies were conducted separately from the pain expectation and pain studies and that the subjects were not aware of any link between the two sets of experiments. The results then reflect intrinsic differences in the response of the NAC during reward anticipation, further defining individual variations in placebo responding.
Individual differences in responses to reward expectation were further examined as a function of whether subjects rated the placebo as more, equally, or less effective than initially anticipated. The group rating the placebo as more effective or equally effective than anticipated also activated the NAC in a manner proportional to the value of expected monetary rewards. However, subjects perceiving the placebo as less effective than anticipated did not show parametric increases in NAC activity as a function of expected reward value. Variations in the processing of expected rewards are therefore shown to reflect the capacity of the individual to respond to placebo administration.
The NAC is a central component of the brain reward system, receiving dense DA projections from the ventral tegmental area. NAC DA neurotransmission is thought to respond to salient stimuli, traditionally studied in the context of the pursuit of natural as well as drug rewards (Berridge and Robinson, 2003; Robinson and Berridge, 2000) , but also to noxious or nonrewarding salient stimuli, including pain (Horvitz, 2000; Scott et al., 2006; Setlow et al., 2003; Zink et al., 2003) . Emerging data suggest, however, that NAC DA mechanisms have a more basic role in the encoding of reward expectancy and variations from expected outcomes, as opposed to a simple response to actual rewards (Berridge and Robinson, 2003; Schultz, 2006; Tobler et al., 2005) . Experimental data in human subjects seems to support this view. NAC synaptic activity, as measured with fMRI, has been shown to increase with the expectation of a monetary reward, but less prominent effects were observed when the reward was actually obtained (Knutson et al., 2001) . From the NAC, it is believed that the incentive signal is transmitted to other loci, such as the ventral pallidum, amygdala, medial thalamus, and prefrontal cortex, areas of importance for the integration and expression of motivated behaviors, the so-called ''motive'' or ''motivation'' network (Kalivas et al., 1999; Mogenson and Yang, 1991) . Notable in this context is the fact that a number of these regions (prefrontal cortex, anterior cingulate, nucleus accumbens, thalamus, and insular cortex) have been shown to respond with synaptic activation (Petrovic et al., 2002; Wager et al., 2004) and the release of endogenous opioids during placebo administration and expectation of analgesia.
In humans, the neural responses to expectancies, gains, and losses have been studied in the context of gambling theory, where the brain responses to potential gains and losses are related to the initial expectations of the individual. Framed in the context of prospect theory (Kahneman and Tversky, 1979) and decision affect theory (Mellers et al., 1997 (Mellers et al., , 1999 , potential gains are evaluated depending on the risk for loss, leading to decisions that disregard the actual gains or losses in monetary terms. For example, the absence of gain is evaluated positively if a loss was expected and negatively if a gain was the initial expectation, albeit the outcome was the same in either case. Positive expectations, outcomes, and counterfactual comparisons, the relationship between anticipated and obtained outcomes, have been shown to linearly increase the activity of the NAC in fMRI studies (Breiter et al., 2001; Knutson et al., 2005; Yacubian et al., 2006; Tom et al., 2007) .
The data presented here demonstrate that placebo responding follows identical patterns, with anticipated placebo effects and the mismatch between anticipated and perceived outcomes (counterfactual comparisons) being linearly related to the activation of NAC DA neurotransmission during placebo administration. Furthermore, the individual neural responses to anticipated monetary rewards tracked the subjects' expectations of analgesia and deviations from those predictions. This demonstrates that placebo-induced neurochemical and psychophysical responses are an example of reward processing, and that individual variations in placebo responding are associated with differences in reward expectation processing. In Knutson et al. (2005) , it was further observed that NAC activity during reward expectation was correlated with selfreported positive arousal. Consistent with the proposed link between reward processing and placebo responses, we observed that increases in positive affect ratings during placebo administration were related to both greater placebo-induced NAC DA release and NAC synaptic activity during monetary reward anticipation.
We demonstrate that NAC DA D2/D3 receptor mediated neurotransmission is activated during the receipt of a placebo in the context of the anticipation of a painful challenge in a manner proportional to the anticipated benefit of the placebo and variations from those predictions. Placebo-associated DA activation in the dorsal caudate and putamen have been shown in Parkinson's disease and related to improvement of motor function (de la FuenteFernandez et al., 2001) . In subsequent analyses of the same trial, these authors also showed NAC DA activation that was related to the individual expectation of functional recovery, but not motor function (de la Fuente-Fernandez et al., 2002) , in a manner similar to what is shown here for expectation of analgesia. The present work therefore generalizes ventral basal ganglia DA neurotransmission as an underlying mechanism across various forms of placeboassociated expectations. This assertion is consistent with the increases in metabolism observed in the ventral basal ganglia when healthy subjects expected a psychostimulant drug (methylphenidate) but instead received a placebo (Volkow et al., 2006) . However, and unlike the previous studies, we also describe that placebo-induced activation of NAC DA during pain expectation predicted placebo-induced analgesic effects in subsequent pain trials. These findings are consistent with the hypothesis that this system is involved in the encoding of the ''incentive value'' of the placebo, possibly acting as a gate or permissive system for the formation of placebo effects. Placebo analgesic effects have been additionally linked to the activation of endogenous opioid neurotransmission, as evidenced by its abolition by the opioid receptor antagonist naloxone (Amanzio and Benedetti, 1999; Levine et al., 1978) or directly through the measurement of endogenous opioid activity with PET . A colocalization of DA D2 receptors with enkephalinergic neurons has been described in the NAC (Badiani et al., 1999; Chen et al., 1993) , which may underlie the involvement of both DA and opioid mechanisms in placebo analgesia.
The information presented here links variations in the function of reward processing and saliency response systems (mesolimbic dopamine, nucleus accumbens synaptic responses) with variations in placebo effects in healthy volunteers. Substantial differences in the magnitude of placebo effects have been described between disease processes, or even between individuals within a disease category (Benedetti et al., 2005 (Benedetti et al., , 2006 Huppert et al., 2004; Keck et al., 2000) . The present results indicate that intrinsic differences in the function of neurobiological mechanisms involved in reward anticipation processing, such as the mesolimbic dopaminergic pathway, explain a substantial proportion of the variance in placebo effects. The placebo effect then emerges as a resiliency mechanism with broad implications that, given its activation of specific circuits and mechanisms, can be both examined and modulated for therapeutic purposes. It also represents an experimental probe that, beyond its confounding properties in the study of potentially therapeutic agents, would help determine dysfunctions in cerebral mechanisms that may impair recovery across a number of conditions.
EXPERIMENTAL PROCEDURES
Subjects
Volunteers were 30 healthy, medication free, right handed men (n = 23) and women (n = 7) 24 ± 3 years of age. Fourteen subjects participated in [
11 C]raclopride PET, fMRI, pain expectation, and pain challenge studies. Sixteen additional subjects underwent identical procedures except that they did not participate in [ 11 C]raclopride PET studies.
A separate sample of 18 healthy males, 20-30 years of age, was studied twice with the same experimental challenges, except that they not receive placebo and were not scanned. This group was utilized to rule out systematic effects of study order in the results.
Subjects had no personal history of medical, psychiatric illness, substance abuse or dependence, and no family history of inheritable illnesses. Volunteers were not taking psychotropic medications or hormone treatments, were nonsmokers, and did not exercise in excess of 1 hr three times a week. Females had regular menstrual cycles and were studied in the follicular phase of the menstrual cycle (days 4-10 after the onset of menses). Menstrual cycle phase was ascertained with estradiol and progesterone (<3 ng/ml) plasma levels immediately prior to scanning. Written informed consent was obtained in all cases. All the procedures employed were approved by the University of Michigan Investigational Review Board for Human Subject Use and the Radiation Drug Research Committee.
Experimental Sequence
The sequence of experimental events is summarized in Figure 1A . Using the time of tracer administration as time 0 min (T0) for the PET studies, a pain anticipation condition (pain is expected and rated, but not received) started at T5 and continued for 20 min (until T25). The anticipation challenges were followed by actual pain challenges starting at T45, lasting for 20 min (until T65). Subjects remained in the scanner during this period of time until T90. In placebo studies, placebo administrations started at T3 and were repeated every 4 min, until T23. In the case of the pain challenges, placebo administrations started at T43, were again repeated every 4 min, and were completed at T63. Rating scales were completed before T0 (baselines) and at T35.
FMRI studies with the MID task were conducted either before or after the PET studies in randomized, counterbalanced order, and were separated from them by 24 to 72 hr, depending on scanner availability and the scheduling needs of the subjects. Subjects were not informed of any connection between fMRI and PET studies, and the experiments were framed in the context of the study of individual variations in the response to various stimuli.
Pain Expectation Condition, Pain Challenges, and Placebo Administration Subjects were placed in the scanner gantry as described under PET Acquisition, below. Needles (25 1/2-gauge) were placed in both masseter muscles 20 min prior to radiotracer (T20) administration. During the pain expectation condition and starting 5 min posttracer administration (T5), nonpainful sterile isotonic saline (0.9%) was introduced at a rate of 75 ml/min in the right masseter muscle via a closed infusion system over 20 min (until T25) . Subjects were asked to rate pain intensity every 15 s using an electronic 0-100 visual analog scale (VAS) placed in front of the scanner gantry. Pain ratings were invariably 0 during this condition. Subjects were informed that the lower end on the scale denotes ''no pain'' while the upper bound represents the ''most pain imaginable.'' However, subjects were instructed to expect pain of moderate intensity (40 VAS units in the 0-100 scale) during the trial. The trials were followed by actual 20 min pain challenges on the left masseter muscle (Stohler and Kowalski, 1999; Zhang et al., 1993) . These challenges started 45 min after tracer administration (T45 to T65), and consisted of the use 5% hypertonic saline solution to elicit a pain signal. Since pain sensitivity is highly variable between individuals, pain was maintained at similar levels of intensity across subjects over time by the use of an adaptive system that utilizes feedback from the subjects. A standard 0.15 ml bolus of 5% NaCl was introduced over 15 s as the initial impulsive input, while recording the subjects pain intensity response every 15 s. A suitable infusion rate was then estimated using a computer controller that compares the subject's pain rating to the mean rating of 65 subjects in the same decade of age exposed to the same bolus. Subsequently, the adaptive controller depends entirely on feedback from subjects. The subject ratings of pain intensity every 15 s. were fed back to the computer via an analog-digital board, and the infusion rate modulated over time to maintain a target pain rating between 30 and 40 VAS intensity units (Stohler and Kowalski, 1999; Zubieta et al., 2001 Zubieta et al., , 2002 Smith et al., 2006) . For the studies including placebo administration, the same individual infusion profiles generated during the pain challenges were employed for the placebo studies. High and low placebo responding during the pain trials was defined using the median values of their average pain ratings over the 20 min of the challenge as threshold.
Subjects were given clinical trial-type instructions prior to administration of the placebo, so that the conditions of the study would be similar to those encountered in typical placebo-controlled drug trials: ''We are studying the effect of a novel medication with analgesic properties. This medication is thought to have analgesic effects through the activation of brain systems that suppress pain.'' In the written consent form, it was further explained that they could receive an active drug, or a substance with no intrinsic pain relief properties.
The placebo condition consisted of the introduction of 1 ml 0.9% isotonic saline into one of the intravenous ports over 15 s, every 4 min, over 20 min, starting 3 min after radiotracer administration (T3-T23 for pain anticipation) and T43-T63 for pain trials. Subjects were informed that the study drug was to be administered by means of a warning that was followed by a second-by-second count of the infusion timing (15 s) using a computer-generated human voice recording. Subjects were also asked to estimate the expected analgesia prior to the introduction of the placebo. After the pain challenges, they were also asked to estimate the analgesic efficacy of the placebo using a VAS scale from 0 (no analgesic effect) to 100 (maximum analgesia).
Upon completion of the pain expectation trials (T35), the subjective experience was additionally evaluated using the Positive and Negative Affectivity Scale (PANAS) (Watson et al., 1988) .
PET and MRI Acquisition
Two PET scans were acquired with a Siemens (Knoxville, TN) HR + scanner in 3-D mode (reconstructed full-width half maximum ÀFWHM-resolution $5.5 mm in-plane and 5.0 mm axially), with septa retracted and scatter correction. Participants were positioned in the PET scanner gantry, and two intravenous (antecubital) lines were placed. A light forehead restraint was used to eliminate intrascan head movement. Subjects remained in the scanner for all procedures (90 min total). Image data was analyzed from 5 to 40 min posttracer administration (pain anticipation condition with and without placebo).
[ 11 C]raclopride was synthesized at high specific activity (>2000 Ci/mmol) by the reaction of O-desmethyl raclopride with 11 C-methyl triflate. Ten to 15 mCi were administered in each of the two scans, with a mass of raclopride injected of 0.20 ± 0.15 mg/kg per scan. Fifty percent of the radiotracer dose was administered as a bolus, and the remaining 50% by continuous infusion for the remainder of the study. Images were reconstructed using iterative algorithms (brain mode; Fourier rebinning with ordered subsets-expectation maximization, 4 iterations, 16 subsets; no smoothing) into a 128 3 128 pixel matrix in a 28.8 cm diameter field of view. Attenuation correction was performed through a 6 min transmission scan ( 68 Ge source) obtained prior to the PET study, also with iterative reconstruction of the blank/transmission data followed by segmentation of the attenuation image. Small head motions during emission scans were corrected by an automated computer algorithm for each subject before analysis, and the images coregistered to each other with the same software (Minoshima et al., 1993) . Time points were then decay-corrected during reconstruction of the PET data. Image data were then transformed on a voxel-by-voxel basis into two sets of parametric maps: (A) a tracer transport measure (K 1 ratio) and (B) a receptor-related measure (Distribution Volume Ratio, DVR) during pain anticipation trials, using data from 5 to 40 min posttracer administration. To avoid the need for arterial blood sampling, these measures were calculated using a modified Logan graphical analysis (Logan et al., 1996) using the cerebellum (an area devoid of dopamine D2 receptors). With the partial bolus-continuous infusion radiotracer administration protocol used, the Logan plot becomes linear by 4 to 5 min after the start of radiotracer administration, allowing the calculation of receptor measures early after tracer administration. The slope of the Logan plot is equal to the (f 2 Bmax/Kd) + 1 for this receptor site (receptor concentration divided by its affinity for the radiotracer) and it has been referred to as the Distribution Volume Ratio, (DVR); f 2 Bmax/Kd (or DVR -1) is the ''receptor related'' measure (also termed binding potential, BP) (Mintun et al., 1984) or receptor availability in vivo. The term f 2 refers to the concentration of free radiotracer in the extracellular fluid and is considered to represent a constant and very small value.
Anatomical MRI scans were acquired on a 3 Tesla scanner (General Electric, Milwaukee, WI). Acquisition sequences were axial SPGR In- , number of excitations [NEX] = 1, using 124 contiguous images, 1.5 mm thickness). K1 and DVR images for each experimental period and MR images were coregistered to each other and to the International Consortium for Brain Mapping (ICBM) stereotactic atlas orientation. Statistical parametric maps of differences between conditions (pain versus baseline) were generated by anatomically standardizing the T1-SPGR MRI of each subject to the ICBM stereotactic atlas coordinates, with subsequent application of this transformation to the DA D2/D3 and m-opioid receptor binding maps. The accuracy of coregistration and nonlinear warping algorithms was confirmed for each subject individually by comparing the transformed MRI and PET images to each other and the ICBM atlas template.
Functional MR images were acquired in the same scanner with a single-shot combined spiral in/out acquisition (Glover and Law, 2001) , gradient echo, TR = 2000 ms, TE = 30 ms, FA = 90, FOV = 20 cm, 64 3 64 matrix. The first five volumes in each session were discarded to allow for T1 equilibration effects. Functional image preprocessing included correction for slice-acquisition timing to the middle slice, realignment to the first volume of each run to correct for intrascan movement, and smoothing with a Gaussian kernel of 8 mm FWHM to compensate for small residual anatomic variations across subjects. Smoothed images were then band pass-filtered with a 128 s high pass filter to eliminate low frequency signals. A general linear model was constructed in SPM2 (Welcome Department of Cognitive Neurology, University College, London, UK) with parameters corresponding to the type of monetary reward anticipated, modeling each session separately. Each stimulus type was convolved with the SPM2 canonical hemodynamic response function.
Monetary Incentive Delay Task
Thirty subjects completed the Monetary Incentive Delay (MID) task in the fMRI scanner (Knutson et al., 2000) . A schematic of the paradigm is presented in Figure 2 . Each MID session consisted of 72 6 s trials: a trial consisted of a cue, followed by a variable delay interval, followed by a button-press response to a target. Subjects were then informed of their success on the preceding trial, as well as their monetary gain or loss. The cue could be one of seven types, representing three different levels of monetary gain ($0.20, $1.00, and $5.00), a null condition ($0), or three levels of monetary loss (À$0.20, À$1.00, and À$5.00). In monetary gain trials, subjects would win the cued amount of money if they successfully responded during the target presentation. In monetary loss trials, subjects had to successfully respond to the target to avoid losing the cued monetary amount. In the null trials, subjects experienced no monetary gain or loss but were still instructed to respond to the target. During a practice session prior to scanning, each subject's reaction time was used to define the presentation time for the target where their success rate in the task would be at least 66%.
Data Analysis
Volumes-of-interest (VOI) in the NAC were first drawn in the ICBM stereotactic atlas orientation template using published boundary guidelines (Martinez et al., 2003) and then transferred to the PET BP maps. No global normalization was applied to the PET data, and therefore the calculations presented are based on absolute BP (f 2 Bmax / Kd) estimates.
The fMRI time series were analyzed using SPM2 and Matlab software. Parameter estimates of event-related activity were established for each voxel, and contrast images were calculated by applying appropriate linear contrasts to the parameter estimates of each event type to produce statistical parametric maps. The main effect of interest was anticipation of large ($5.00) reward versus null ($0.00) reward. The resulting statistical image for each subject was then spatially normalized into ICBM space by applying the T1-SPGR transformation parameters to the SPM2 contrast image. NAC VOIs were then applied to the normalized contrast images ( Figure 3A) . BOLD activations were extracted from fMRI data to calculate percent change for each event. These extractions were performed using the Marsbar region of interest toolbox for SPM (version 0.38). Raw BOLD intensity data was then extracted from each ROI for each subject and used to determine percent change, which was calculated as the average local BOLD intensity during large reward anticipation divided by the average local BOLD intensity during null anticipation, multiplied by 100.
Differences in psychophysical measures, BP and BOLD signal in the NAC were tested with one-tail paired t tests, at p < 0.05 for within subject conditions (effects of placebo) because of the expected directionality of the results. One-tail unpaired t tests were utilized for between subject analyses (high versus low placebo responders) at p < 0.05. Correlations between variables were tested with Pearson correlations at p < 0.05. Other comparisons are described in the text. Data in the text is expressed as the mean ± 1 SD.
